loading page

Incidence of leukemia in Eritrea: 11-year Laboratory -based retrospective analysis of nationally representative data
  • +8
  • Daniel Mebrahtu Abraha,
  • Efriem Ghirmay,
  • Eden Gebretinsae,
  • Ghirmay Embaye Zerat,
  • Rahwa Kokob,
  • Tsega Daniel,
  • Asmeret Tesfazghi,
  • Solomon Negash,
  • Salih Mohammed,
  • Samuel Tekle,
  • Oliver Okoth Achila
Daniel Mebrahtu Abraha
National Health Laboratory

Corresponding Author:[email protected]

Author Profile
Efriem Ghirmay
National Food and Medicine Administration
Author Profile
Eden Gebretinsae
Orotta National Referral Hospital
Author Profile
Ghirmay Embaye Zerat
National Health Laboratory
Author Profile
Rahwa Kokob
Orotta National Referral Hospital
Author Profile
Tsega Daniel
National Health Laboratory
Author Profile
Asmeret Tesfazghi
Orotta National Referral Hospital
Author Profile
Solomon Negash
Orotta National Referral Hospital
Author Profile
Salih Mohammed
National Health Laboratory
Author Profile
Samuel Tekle
Nakfa Hospital
Author Profile
Oliver Okoth Achila
Orotta College of Medicine and Health Sciences
Author Profile

Abstract

Little or no research has been conducted on the epidemiology of leukemias in Eritrea . In this retrospective study, we evaluated the burden and trends of acute lymphoblastic leukemia (ALL), Acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL) and overall leukemia in Eritrea. Methods: An audit of leukemia cases recorded in laboratory logbooks at the National Health Laboratory (NHL) and Orotta Referral and Teaching Hospital (ORTH) between January 2010 and December 2021 was performed. Aside from leukemia sub-types, additional variables that were retrieved included age, sex, years of incidence, residency. Relevant estimates assessed included crude incidence rates (CIR), age-standardised rates (ASIR) and estimated annual percentage change (EAPC). Results: In total, 372 confirmed cases of leukemia were recorded between, 2010-2020. The median [interquartile range (IQR)] age, maximum – minimum age, and male/female ratio were as follows: 48 years (24.5 – 60 years), 2 - 91 years, and 210/161 (1.3: 1), respectively. Estimated all-age CIR and ASIR over the study period was 9.22 per 100 000 and 30.1 per 100 000 respectively. Analysis of cumulative (2010 - 2020) CIR per 100 000 (ASIR per 100 000) for ALL, AML, CLL, and CML were as follows: 2.01(3.87); 0.94(2.38); 2.94(15.37) and 3.61(24.03). Additionally, median (IQR) age differed significantly across different subtypes of leukemia – ALL (23.0 years, IQR: 10.0 – 39.0); AML (30 years, IQR: 20 – 56 years), CLL (59.0 years, IQR: 40.75 – 66.75 years), and CML (49 years, IQR: 39.25 – 60 years), p value (Kruskal Wallis), < 0.05). No sex specific differences were observed in median (IQR) for different types of leukemia. Unlike other leukemia sub-types evaluation of EAPC demonstrated that the incidence of leukemia has increased overtime, 21.9 (95 CI: 3.1-44.1), p-value = 0.025. Conclusions: The burden of leukemia was relatively stable . However, due to underreporting and underdiagnosis, it’s our belief that the true burden of leukemia is likely higher. Further, an upward trend in the burden of ALL was uncovered. Lastly, expansion of diagnostic services to other sub-zones, establishment of a national cancer registry and research remains a priority in Eritrea.
11 Sep 2024Submitted to Cancer Reports
11 Oct 2024Submission Checks Completed
11 Oct 2024Assigned to Editor
11 Oct 2024Review(s) Completed, Editorial Evaluation Pending
12 Oct 2024Reviewer(s) Assigned
10 Dec 2024Editorial Decision: Revise Major